8DU3 image
Entry Detail
PDB ID:
8DU3
Title:
Crystal structure of A2AAR-StaR2-bRIL in complex with compound 21a
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-07-26
Release Date:
2022-08-10
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.19
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Adenosine receptor A2a, soluble cytochrome b562 chimera,Soluble cytochrome b562,Adenosine receptor A2a
Mutations:A79L, T113A, R132A, K147A, N179A, L227A, M240W, H335I, R339L, L356A, V360A, S398A
Chain IDs:A
Chain Length:447
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
High ligand efficiency quinazoline compounds as novel A 2A adenosine receptor antagonists.
Eur.J.Med.Chem. 241 114620 114620 (2022)
PMID: 35933788 DOI: 10.1016/j.ejmech.2022.114620

Abstact

The past fifty years have been marked by the surge of neurodegenerative diseases. Unfortunately, current treatments are only symptomatic. Hence, the search for new and innovative therapeutic targets for curative treatments becomes a major challenge. Among these targets, the adenosine A2A receptor (A2AAR) has been the subject of much research in recent years. In this paper, we report the design, synthesis and pharmacological analysis of quinazoline derivatives as A2AAR antagonists with high ligand efficiency. This class of molecules has been discovered by a virtual screening and bears no structural semblance with reference antagonist ZM-241385. More precisely, we identified a series of 2-aminoquinazoline as promising A2AAR antagonists. Among them, one compound showed a high affinity towards A2AAR (21a, Ki = 20 nM). We crystallized this ligand in complex with A2AAR, confirming one of our predicted docking poses and opening up possibilities for further optimization to derive selective ligands for specific adenosine receptor subtypes.

Legend

Protein

Chemical

Disease

Primary Citation of related structures